BioSpace News Archive

Zynex, Inc. announced the pricing of its previously announced underwritten public offering of an aggregate of 2,500,000 shares of its common stock at a public offering price of $22.00 per share.

While studying the effects of androgens on hair loss, Applied Biology scientists discovered an association between cellular receptors that predispose an individual to develop common hair loss (androgenetic alopecia) and COVID-19.

Gateway Health, a leading managed care organization focused on the total health of its members, today announced Ja’Ron Bridges has joined the organization as Senior Vice President and Chief Financial Officer (CFO).

Dr. George Sadowski, M.D., founder, and Chief Medical Officer for Nourishing Biologicals (NB), has published a revolutionary study, “Safety and Efficacy of a Novel Antiaging Skin Care Regimen Containing Nutraceuticals and Growth Factors on the Facial Skin of Women” in The Journal of Clinical and Aesthetic Dermatology.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that Keith J. Sullivan has been appointed as the company’s President and Chief Executive Officer and has joined the Board of Directors effective immediately. “The Neuronetics Board of Directors is very happy to complete our rigorous CEO search with the hiring of Keith Sulliva

Zynex, Inc. (“Zynex”) (Nasdaq: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it is commencing an underwritten public offering of shares of its comm

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announces its second quarter fiscal 2020 results. Brian Pedlar, Covalon’s President and CEO, said, “Like all businesses everywhere in the world, Covalon has been severely impacted by the COVID-19 pandemic. In response, the entire Covalon team has been working very hard to generate sa

Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273) Interim analysis of original cohorts of Phase 1 study evaluated two-dose vaccination schedule of mRNA-1273 across three dose levels (25, 100, 250 µg) in 45 healthy adults ages 18-55 years; results reaffirm and expand upon positive interim data announced on May 18 th Neutralizing antibody titers we

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic